BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Special

Plastic, Steel and Software: APAC’s Next-Generation Bioprocessing Choice

When a biologics manufacturer in Bengaluru, Songdo or Singapore signs off on a new production suite today, the hardest question is rarely which molecule to...

June 23, 2026 | Analysis

After the Drug Substance, the Real Squeeze: APAC's Aseptic Fill-Finish Gap

For most of the last decade, the anxiety in Asia-Pacific biomanufacturing pointed upstream. The conversation was about bioreactor volume — how many t...

June 22, 2026 | Analysis

Billions on Bioconjugation: Is APAC Building the Right ADC Capacity — or Too Much?

In Songdo, on the reclaimed waterfront west of Seoul, a 202,000-square-metre construction site is becoming the most expensive single statement Kore...

June 19, 2026 | Analysis

World-Class Plants, Who Will Run Them? APAC's Biomanufacturing Skills Gap

Walk into one of the gleaming new large-molecule plants going up across Songdo, Tuas or Hyderabad and the first impression is of inevitability. The...

June 18, 2026 | Analysis

Agility or Corner-Cutting? Asia's Accelerated-Approval Gamble

On 1 April 2026, Japan's Pharmaceuticals and Medical Devices Agency did something no other major medicines regulator had done before it: from that date, ev...

June 17, 2026 | Analysis

AI Must Shift Healthcare From Crisis Response To Early Intervention Across APAC

As healthcare systems across Asia Pacific confront mounting workforce shortages, ageing populations, and rising chronic disease burdens, artificial intelli...

June 10, 2026 | News

Curative but Unaffordable: Gene and Cell Therapy's Access Paradox in Asia

At almost every cell-and-gene-therapy conference in the region, the same slide appears: a child who was dying of leukaemia, now in durable remission; a tee...

June 03, 2026 | Analysis

Advancing NAD Biomarkers From Research Discovery To Clinical Reality

As interest in metabolic health, longevity science, and precision medicine continues to grow, the ability to accurately measure biological markers linked t...

June 03, 2026 | Interview

Scientific Infrastructure or Expensive Theatre? AI Discovery’s Reckoning in Asia

In October 2025, Eli Lilly announced it would build the most powerful supercomputer ever owned by a drug company. By February 2026, “LillyPod” ...

June 02, 2026 | Analysis

When America Builds a Wall: Who Inherits China’s Displaced Biotech Work?

When President Trump signed the FY2026 National Defense Authorization Act on December 18, 2025, the biopharmaceutical industry finally got the law it had s...

June 02, 2026 | Analysis | By arcilla.fran@biopharmaapac.com

Quantum Breakthrough Enables Largest Ever Protein Simulations Advancing Drug Discovery Potential

Scientists at Cleveland Clinic, RIKEN, and IBM (NYSE: IBM) have used IBM quantum computers and two of the world's most powerful supercomputers to simu...

May 06, 2026 | News

Alar Pharmaceuticals Reports Positive Phase 1 Results For ALA 3000 In Treatment Resistant Depression

By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, impr...

April 08, 2026 | News

From Staging to Survival: How AI-Driven Histological Analysis Is Solving Colorectal Cancer's Overtreatment Problem

The hidden cost of getting treatment decisions wrong Colorectal cancer (CRC) is one of the most prevalent and lethal cancers worldwide, ranking among the ...

April 02, 2026 | Expert Insight | By Dr. Torbjørn Furuseth, CEO and Co-Founder, DoMore Diagnostics

Taiwan Strengthens Its Position In Asia’s Next Phase Of Bioprocessing Growth

Taiwan’s bioprocessing and biotechnology sector has moved from a predominantly research-and-services footing toward a more industrialised, globally c...

March 20, 2026 | Analysis

Stay Connected